Terms: = Sarcomas AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
74 results:
1. Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma.
Wei L; Meng J; Xiang D; Yang Q; Zhou Y; Xu L; Wang M; Chen J; Han Y
BMC Complement Med Ther; 2024 Jan; 24(1):67. PubMed ID: 38297292
[TBL] [Abstract] [Full Text] [Related]
2. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
3. The anti-oncogenic effect of 17-DMAG via the inactivation of hsp90 and MET pathway in osteosarcoma cells.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Kubota Y; Tsumura H
Oncol Res; 2023; 31(5):631-643. PubMed ID: 37547755
[TBL] [Abstract] [Full Text] [Related]
4. Study on the mechanism of Shujin Tongluo granules in treating cervical spondylosis based on network pharmacology and molecular docking.
Wang Y; Tao X; Gao Y; Jin Z; Guo S; Li Z; Wang M; Zhao R; Zhou W; Wu J
Medicine (Baltimore); 2023 Jul; 102(29):e34030. PubMed ID: 37478234
[TBL] [Abstract] [Full Text] [Related]
5. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Naito Y; Nishida T; Doi T
Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
[TBL] [Abstract] [Full Text] [Related]
6. Based on network pharmacology and bioinformatics to analyze the mechanism of action of Astragalus membranaceus in the treatment of vitiligo and COVID-19.
Wang Y; Ding M; Chi J; Wang T; Zhang Y; Li Z; Li Q
Sci Rep; 2023 Mar; 13(1):3884. PubMed ID: 36890149
[TBL] [Abstract] [Full Text] [Related]
7. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel hsp90 C-terminal domain inhibitors against Ewing sarcoma.
Zajec Ž; Dernovšek J; Distel M; Gobec M; Tomašič T
Bioorg Chem; 2023 Feb; 131():106311. PubMed ID: 36495678
[TBL] [Abstract] [Full Text] [Related]
8. FOXO3a-dependent up-regulation of hsp90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells.
Lu D; Liu R; Zhou Y; Zhang Z; Jiang X; Xu J; Su A; Hu Z
Cell Signal; 2023 Jan; 101():110500. PubMed ID: 36270475
[TBL] [Abstract] [Full Text] [Related]
9. In Silico Discovery and Optimisation of a Novel Structural Class of hsp90 C-Terminal Domain Inhibitors.
Zajec Ž; Dernovšek J; Gobec M; Tomašič T
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883440
[TBL] [Abstract] [Full Text] [Related]
10. Canine osteosarcoma cells exhibit basal accumulation of multiple chaperone proteins and are sensitive to small molecule inhibitors of GRP78 and heat shock protein function.
Mattos DR; Weinman MA; Wan X; Goodall CP; Serrill JD; McPhail KL; Milovancev M; Bracha S; Ishmael JE
Cell Stress Chaperones; 2022 May; 27(3):223-239. PubMed ID: 35244890
[TBL] [Abstract] [Full Text] [Related]
11. hsp90 regulates the tumorigenic function of tyrosine protein kinase in osteosarcoma.
Yao ZP; Zhu H; Shen F; Gong D
Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):380-390. PubMed ID: 34767669
[TBL] [Abstract] [Full Text] [Related]
12. TAS-116 (Pimitespib), an Oral hsp90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
[TBL] [Abstract] [Full Text] [Related]
13. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation hsp90 inhibitor in Saos-2 osteosarcoma cells.
Özgür A
J Chemother; 2021 Dec; 33(8):554-563. PubMed ID: 33794753
[TBL] [Abstract] [Full Text] [Related]
14. Mild microwave ablation combined with hsp90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma.
Chen L; Wang M; Lin Z; Yao M; Wang W; Cheng S; Li B; Zhang Y; Yin Q
Mol Med Rep; 2020 Aug; 22(2):906-914. PubMed ID: 32468060
[TBL] [Abstract] [Full Text] [Related]
15. hsp90 inhibitor 17‑AAG inhibits stem cell‑like properties and chemoresistance in osteosarcoma cells via the Hedgehog signaling pathway.
Shu X; Liu H; Zhen R; Jie Y; Chen L; Qi H; Wang C; Wang R; Chen D; Ran Y
Oncol Rep; 2020 Jul; 44(1):313-324. PubMed ID: 32377704
[TBL] [Abstract] [Full Text] [Related]
16. The Major Heat Shock Proteins, Hsp70 and hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model.
Gorska-Ponikowska M; Kuban-Jankowska A; Marino Gammazza A; Daca A; Wierzbicka JM; Zmijewski MA; Luu HH; Wozniak M; Cappello F
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963524
[TBL] [Abstract] [Full Text] [Related]
17. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/hsp90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract] [Full Text] [Related]
18. Iron-oxide nanoparticles target intracellular hsp90 to induce tumor radio-sensitization.
Shetake NG; Kumar A; Pandey BN
Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):857-869. PubMed ID: 30794824
[TBL] [Abstract] [Full Text] [Related]
19. hsp90aa1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract] [Full Text] [Related]
20. A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and sarcomas.
Meehan R; Kummar S; Do K; O'Sullivan Coyne G; Juwara L; Zlott J; Rubinstein L; Doroshow JH; Chen AP
Oncologist; 2018 Nov; 23(11):1269-e125. PubMed ID: 29853657
[TBL] [Abstract] [Full Text] [Related]
[Next]
